CJC-1295 (With DAC)Secretagogue PeptideBlendSafety Rating 5/10
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Price Comparison
Compare vendors · per 5mg
| Vendor | Price | $ / mg | Updated | |
|---|---|---|---|---|
| PeptiraBest $/mgCOA ✓ · 3P | $39.00 | $7.80 | May 14, 2026 | Buy → |
| SomaChemsCOA ✓ · 3P | $43.99 | $8.80 | May 14, 2026 | Buy → |
| Modern AminosCOA ✓ · 3P | $48.00 | $9.60 | May 14, 2026 | Buy → |
| Olympex SolutionsCOA ✓ · 3P | $49.99 | $10.00 | Apr 6, 2026 | Buy → |
| Biotech PeptidesCOA unknown | $52.00 | $10.40 | May 14, 2026 | Buy → |
Overview
About CJC-1295
Mechanism of action
GHRH analogue with Drug Affinity Complex that covalently binds albumin, dramatically extending half-life. Causes sustained GH release ('GH bleed') vs. pulsatile pattern.
Safety profile
Water retention, lethargy, joint pain, insulin resistance, potential blunting of natural GH pulsatility with prolonged use. · Human PK data available; one unexplained death in trials (possibly unrelated); longer half-life
Storage
Stability & handling
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops CJC-1295 below your target.
Safety & Interactions
Contraindications & Drug Interactions
Research use only — not medical advice. Consult a licensed physician before using any peptide. Sources are cited where available.
Active malignancy — sustained GH/IGF-1 elevation.
One unexplained death reported in Phase 1 trials (possibly unrelated). Long half-life (~1 week) complicates dose adjustments.
Type 2 diabetes — extended GH exposure worsens insulin sensitivity more than No-DAC variant.
Blend
Component Compounds
CJC-1295 (No DAC)
GHRH receptor agonist · half-life 30 min–2 hrs
Ipamorelin
Aib-His-D-2-Nal-D-Phe-Lys-NH₂Ghrelin receptor (GHSR-1a) agonist · no cortisol/prolactin elevation
Related pages
More on CJC-1295
Stack & Compare
Frequently Researched Together
Research
Studies & key findings
- CJC-1295 is a tetrasubstituted GHRH(1-29) analogue bearing a maleimido-propionyl group at its C-terminus that covalently binds to endogenous serum albumin after injection — extending its half-life to approximately 6–8 days compared to the minutes-long half-life of native GHRH, enabling once-weekly dosing.
- The landmark Phase 1/2 human study (JCEM 2006, Teichman et al.) demonstrated that a single subcutaneous injection of CJC-1295 at 30–60 µg/kg produced sustained, dose-dependent increases in GH (2–10 fold) and IGF-1 (1.5–3 fold) lasting up to 14 days, with excellent tolerability and no serious adverse events in healthy adults.